Bicara Therapeutics Inc. Common Stock (BCAX) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Very high liquidity ⢠No revenue ⢠Sustained cash burn BCAX has a very strong liquidity and low-leverage balance sheet but no revenue and persistent operating cash burn that is rapidly depleting its cash reserves.
Price Behavior
Key Price Behavior Insights: ⢠Steep uptrend ⢠Nearâterm resistance ⢠Pullback risk Support Level: $16.20â$17.60 Resistance Level: $20.06 Over the last month BCAX has rallied ~36% from $14.06 to $19.19, trading ~12% above its last-month SMA (~$17.20) with clear upward momentum but facing resistance near $20.06 and elevated pullback risk.
Sentiment & News
Key News Insights: ⢠Oversubscribed offering ⢠Promising Phase 1b ⢠Active investor outreach Bicara Therapeutics closed an oversubscribed offering that raised ~$172.5M while advancing Phase 1b ficerafusp alfa data, ramping investor engagement and hiring to fund development.
AI Summary
BCAX has shifted from a financing-risk story to a binary clinicalâexecution bet after an oversubscribed $172.5M raiseâmeaning nearâterm value now hinges on Phase 3/interim readouts translating Phase 1b signals rather than on balanceâsheet survival. Actionable focus: monitor interim readout timing (midâ2027), enrollment pace and burn vs. planned Phaseâ3 cadence, and model midâsingleâdigit to material dilution if timelines slip.
Description
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is a bifunctional antibody that combines an EGFR-targeting monoclonal antibody with a domain that binds TGF-β. Founded in 2018 and based in Boston, the company is a subsidiary of Biocon Limited.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 19 | Mar 26 | BCAX | Bicara Therapeutics Inc. Common Stock | BCAX has materially extended its cash runway via a ~$172.5M equity raise and is entering a data-rich 2026 with positive Phase 1b signals and multiple planned FORTIFI-HN01/expansion cohort updates; after a ~20% 21-day rise and clear clinical catalyst calendar, it offers a speculative event-driven upside opportunity in the very near term. | Active | +0.0% |